scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX...
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
August 12, 2024 09:48 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
August 12, 2024 06:05 ET
|
scPharmaceuticals, Inc.
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal;...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
August 12, 2024 06:04 ET
|
scPharmaceuticals, Inc.
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class ...
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
August 12, 2024 06:02 ET
|
scPharmaceuticals, Inc.
SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative...
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
August 12, 2024 06:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the...
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
August 08, 2024 16:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease
July 25, 2024 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the...
scPharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents...